Back

Prognostic value of follow-up hemodynamics after initial treatment in pulmonary arterial hypertension

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Impact of pulmonary hypertension on quality of life and survival Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Daniele Guarino

S. Orsola-Malpighi Policlinic, Bologna (Italy)

7 More presentations in this session

Presentation thumbnail
Comparison of pulmonary arterial risk assessment tools to predict mortality or morbidity in treatment naive and previously diagnosed patients.
Doctor C. Fauvel (Rouen, FR)
Abstract Slides Video
Presentation thumbnail
Multiparametric risk predictions for morbidity and mortality in patients with pulmonary arterial hypertension: insights from a nation-wide registry
Professor C. Kaymaz (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
Acute vasoreactivity testing for severe pulmonary hypertension associated with lung disease
Doctor R. Takano (Suita, JP)
Abstract Slides Video
Presentation thumbnail
Health care utilisation in patients with mild pulmonary hypertension - EVIDENCE-PAH UK study
Doctor N. Karia (London, GB)
Abstract Slides Video
Presentation thumbnail
Does the presence of severe pulmonary hypertension affect survival at 5 years follow-up in patients who underwent TAVI for severe aortic stenosis?
Doctor H. Mohiaddin (Leicester, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Impact of pulmonary hypertension on quality of life and survival

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Volume-pressure loop hemodynamic characterization of pulmonary hypertension
thumbnail
Congress Presentation
Long-term survival outcomes and baseline hemodynamics in patients with PAH versus CTEPH
thumbnail
Congress Presentation
Adults with congenital heart disease and pulmonary arterial hypertension: Quantitative assessment of haemodynamic parameters under disease targeting therapy - A retrospective multicentre analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources